SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases

SGLT2 inhibitors have demonstrated a class effect in improving serum magnesium levels patients with diabetes. Additionally, recent reports shown their promising beneficial effects the treatment of refractory hypomagnesemia However, role treating without diabetes remains unexplored. Here, we report four cases severe and that showed dramatic improvement after initiating Case 1 had calcineurin inhibitor-associated hypomagnesemia. Cases 2, 3, 4 associated platinum-based chemotherapy or gastrointestinal losses. was able to withdraw from high-dose oral supplementation. 2 3 achieved independence intravenous (IV MgSO4) supplementation, while case decreased requirements. All sustainably improved levels. Withdrawal resulted worsening The extra-glycemic benefit this group medications not only suggests need for further studies better understand on homeostasis but also supports expanded use larger patient population.